Thomas Reynolds, formerly chief medical officer at Seattle Genetics Inc, has joined the board of directors of Oxford BioTherapeutics Ltd, which is developing antibody-drug conjugates for cancer. Dr Reynolds has held senior development roles in the biotech industry for more than 20 years including directing medical affairs at ZymoGenetics Inc and managing clinical affairs at Targeted Genetics Corp.
Dr Reynolds earned a medical degree as well as a PhD in biophysics at Stanford University where he subsequently conducted postdoctoral research. He also holds a degree in chemistry from Dartmouth College.
Oxford BioTherapeutics announced the appointment on 15 January 2014.
Copyright 2014 Evernow Publishing Ltd